Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart algorithm keep depression from returning?

NCT ID NCT07779330

Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This trial tests a personalized approach to maintaining improvement in people with treatment-resistant depression. Participants who previously responded to a type of brain stimulation called iTBS will receive maintenance stimulation scheduled by a symptom-based algorithm, along with wearable sensors to detect early signs of relapse. The goal is to see if this combination can keep depression at bay and reduce the chance of it coming back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Individualized brain stimulation (iTBS) guided by brain scans, plus a symptom-based algorithm to schedule retreatment
What this could lead to
If successful, this approach could help people with hard-to-treat depression stay well longer and catch relapses early, reducing the need for frequent hospital visits.
What could go wrong
This is a small, early-stage study without a comparison group, so results may not apply broadly. Brain stimulation can cause side effects like headache or discomfort, and the algorithm may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male/ female aged ≥ 21 to ≤ 70 years old * Able to give informed consent * Able to understand English * DSM-V diagnosis of current/ past major depressive disorder (MDD) episode * Non-response to an adequate trial (4 weeks) of at least 1 MDD medication as verified by a study clinician * Ability to comply with passive wearable use and weekly mobile assessments * Have previously completed a course of individualized, functional connectivity-guided accelerated iTBS and shown a clinical response (as defined by a ≥50% improvement in MADRS score against baseline, any time within 3 months following an acute iTBS course) * Able to comply with the full 12-month protocol inclusive of continuous digital monitoring Exclusion Criteria: * DSM-5 psychotic disorder * Drug or alcohol abuse or dependence (preceding 3 months) * Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy * Metal in the cranium, skull defects, pacemaker, cochlear implant, medication infusion pump or any other electronic implants or devices * Tattoos containing ferromagnetic ink or permanent piercings * Pregnancy * Currently on multiple CNS stimulant medications (2 or more at maximal clinical doses) * Participant does not have the capacity to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder Depressive Disorder, Treatment-Resistant Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National University Hospital, Singapore

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.